Based on its test results to date, the US Food and Drug Administration 1 November again refrained from calling for consumers and patients to stop taking ranitidine products due to concerns about nitrosamine impurities that could cause cancer.
Agency tests found the N-Nitrosodimethylamine (NDMA) nitrosamine impurity in a range of oral solid and oral liquid dosage forms from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?